Clinical Trials Directory

Trials / Terminated

TerminatedNCT00581191

Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SLV-351 Administered Orally to Healthy Subjects

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
72 (estimated)
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer · Industry
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

Safety and tolerability of single oral doses in healthy subjects.

Conditions

Interventions

TypeNameDescription
DRUGSLV-351SLV-351 capsules taken once

Timeline

Start date
2008-01-01
Primary completion
2008-03-01
Completion
2008-03-01
First posted
2007-12-27
Last updated
2009-08-04

Source: ClinicalTrials.gov record NCT00581191. Inclusion in this directory is not an endorsement.